Clarity™ EGFR

T790M Mutation

Quantification Kit

The C2615T mutation results in an amino acid substitution at position 790 in human epidermal growth factor receptor (EGFR), from a threonine (T) to a methionine (M). Patients who develop T790M mutation acquire resistance to first line EGFR tyrosine kinase inhibitor therapy and as such, monitoring the T790M mutation status is crucial to guide treatment decisions. The Clarity™ EGFR T790M Mutation Quantification Kit provides ready-to-use reagents optimized for sensitive detection and quantification of T790M mutant DNA from human plasma or serum using the Clarity™ digital PCR system.

Precise quantification of T790M mutation abundance

Detect as low as 0.1% of T790M mutant DNA

Low hands-on-time, compatible with most conventional thermal cyclers

Analyze up to 96 reactions in 4 hours

T790M

Clarity™ EGFR

L858R Mutation

Quantification Kit

The T2573G mutation results in an amino acid substitution at position 858 in human
epidermal growth factor receptor (EGFR), from a leucine (L) to an arginine (R). The L858R mutation accounts for the majority of EGFR-mutated non-small cell lung cancer (NSCLC), and it displays higher sensitivity to first line EGFR tyrosine kinase inhibitor therapy as compared to wild type EGFR. Therefore, monitoring L858R mutation status is crucial for the prescription of targeted therapies and prediction of their clinical responses. The Clarity™ EGFR L858R Mutation Quantification Kit provides ready-to-use reagents optimized for sensitive detection and quantification of L858R mutant DNA from human plasma or serum using the Clarity™ digital PCR system.

Precise quantification of L858R mutation abundance

Detect as low as 0.1% of L858R mutant DNA

Low hands-on-time, compatible with most conventional thermal cyclers

Analyze up to 96 reactions in 4 hours

Clarity™ EGFR L858R Mutation Quantification Kit

Clarity™

Epstein-Barr Virus

Quantification Kit

Epstein-Barr Virus (EBV) is a double-stranded DNA γ-herpesvirus associated with different malignancies. Quantification of the EBV DNA load has shown to be beneficial for early disease diagnosis as well as accurate monitoring of treatment responses. The Clarity™ EBV Quantification Kit is developed for sensitive detection and quantification of EBV DNA using the Clarity™ digital PCR system (Cat. No. 10001). The kit detects both the single-copy Epstein-Barr nuclear antigen-I (EBNA-I) as well as the multi-copy BamHI-W gene, enabling quantitative and qualitative measurements of EBV DNA isolated from human plasma or serum.

Precise quantification of EBV specific DNA

Optimized to detect < 0.5 copy/μL reaction

Low hands-on-time, compatible with most conventional thermal cyclers

Analyze up to 96 reactions under 4 hours

EBV

Clarity™

Hepatitis B Virus

Quantification Kit

The hepatitis B virus (HBV) is a global human pathogen that causes transient and chronic infections of the liver. The virus can be transmitted by contact with blood or other body fluids from an infected patient. Accurate detection and quantification of HBV DNA plays a vital role in diagnosing HBV infection and monitoring the efficacy of antiviral therapy. The Clarity™ HBV quantification kit is developed for sensitive and precise quantification of HBV DNA from human blood samples, and targets the S region of all HBV genotypes (A-H).

Precise quantification of DNA from all 8 HBV genotypes

Optimized to detect < 0.5 copy/µL reaction

Low hands-on-time, compatible with most conventional thermal cyclers

Analyze up to 96 reactions under 4 hours

HBV kit

Clarity™

Major and Minor

BCR-ABL Mutation

Quantification Kits

 Chronic myeloid leukaemia (CML) and acute lymphoblastic leukemia (ALL) are characterized by the generation of Philadelphia (Ph) chromosome which arises from translocation between chromosomes 9 (region q34: ABL) and 22 (region q11: BCR). This translocation results in the formation of BCR-ABL fusion gene whereby majority of the breakpoints occurs in two regions; after the 13th exon resulting in a b2a2 (e13a2) fusion or after the 14th exon resulting in a b3a2 (e14a2) fusion. These fusions are mostly detected in CML patients and are translated into the constitutively active tyrosine kinase of 210kDa (P210). In Ph-positive ALL patients, the breakpoint typically occurs in the region after the 1st exon, resulting in the formation e1a2 fusion. This e1a2 fusion mRNAs are translated into the P190 constitutively active tyrosine kinase. Molecular detection and quantification of the BCR-ABL fusions are essential for disease diagnosis, monitoring of therapeutic responses and minimal residual disease detection.

Precise quantification of b2a2, b3a2 or e1a2 mutation abundance

Detect as low as 0.1% of b2a2, b3a2 or e1a2 mutant cDNA

Low hands-on-time, compatible with most conventional thermal cyclers

Analyze up to 96 reactions under 4 hours

BCR-ABL

Request a kit brochure

Name (required)


Email (required)


Organization (required)


Kit name (required)